The Healthy Aging Company is a privately owned biopharmaceutical company with a dual presence in the United States, and France dedicated to transforming the landscape of age-related disease treatment.
Focuses on developing first-in-class drug candidates that target Type 2 Diabetes Mellitus (T2DM) and its complications, striving to redefine patient care and disease management.
THAC is a resident at the University of South Florida Research Innovation Park (US)
Registered in Delaware
Founded in Paris, France in partnership with Inserm and Universite Paris Cite.
At the forefront of innovation, THAC is spearheading a revolutionary approach to tackling T2DM, neuropathy, and Alzheimer’s disease by targeting insulin resistance, the root cause of these debilitating conditions. Our drug candidates leverage a unique mechanism of action to combat oxidation and inflammation while directly modulating the gut microbiome, unlocking unprecedented potential for improved patient outcomes.
This transformative therapy offers the promise of:
